[go: up one dir, main page]

TWI365191B - Vaccine - Google Patents

Vaccine

Info

Publication number
TWI365191B
TWI365191B TW094126452A TW94126452A TWI365191B TW I365191 B TWI365191 B TW I365191B TW 094126452 A TW094126452 A TW 094126452A TW 94126452 A TW94126452 A TW 94126452A TW I365191 B TWI365191 B TW I365191B
Authority
TW
Taiwan
Prior art keywords
vaccine
Prior art date
Application number
TW094126452A
Other languages
English (en)
Other versions
TW200621806A (en
Inventor
Helge Abrecht
Martine Delchambre
Martine Marchand
Nathalie Louise Mathy
Philippe Jean Gervais Ghislain Permanne
Gerald Hermann Voss
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of TW200621806A publication Critical patent/TW200621806A/zh
Application granted granted Critical
Publication of TWI365191B publication Critical patent/TWI365191B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW094126452A 2004-08-05 2005-08-03 Vaccine TWI365191B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine

Publications (2)

Publication Number Publication Date
TW200621806A TW200621806A (en) 2006-07-01
TWI365191B true TWI365191B (en) 2012-06-01

Family

ID=32982606

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094126452A TWI365191B (en) 2004-08-05 2005-08-03 Vaccine

Country Status (32)

Country Link
US (2) US7612173B2 (zh)
EP (3) EP1773999B1 (zh)
JP (3) JP2008507987A (zh)
KR (1) KR101501495B1 (zh)
CN (2) CN102633866B (zh)
AR (2) AR050102A1 (zh)
AT (1) ATE443769T1 (zh)
AU (1) AU2005268856B2 (zh)
BR (1) BRPI0514108A (zh)
CA (1) CA2575898C (zh)
CY (1) CY1109667T1 (zh)
DE (1) DE602005016810D1 (zh)
DK (1) DK1773999T3 (zh)
ES (3) ES2486669T3 (zh)
GB (1) GB0417494D0 (zh)
HK (1) HK1108168A1 (zh)
HR (1) HRP20090678T1 (zh)
IL (2) IL180947A0 (zh)
MA (1) MA28983B1 (zh)
MX (1) MX2007001515A (zh)
MY (1) MY145614A (zh)
NO (1) NO20070988L (zh)
NZ (1) NZ552976A (zh)
PE (1) PE20060577A1 (zh)
PL (1) PL1773999T3 (zh)
PT (1) PT1773999E (zh)
RU (1) RU2441878C2 (zh)
SG (1) SG155206A1 (zh)
SI (1) SI1773999T1 (zh)
TW (1) TWI365191B (zh)
WO (1) WO2006013106A2 (zh)
ZA (1) ZA200700771B (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
EP1039880A1 (en) * 1998-10-23 2000-10-04 Idea Innovative Dermale Applikationen GmbH Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
TW200716750A (en) * 2005-05-12 2007-05-01 Glaxo Group Ltd Vaccine composition
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
PT2048955E (pt) * 2006-07-21 2013-09-20 California Inst Of Techn Administração de gene alvo para vacinação de células dendríticas
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
US9717788B2 (en) * 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
US20110244496A1 (en) * 2007-03-06 2011-10-06 Rutgers, The State University Hiv reverse transcriptase compositions and methods
EP2142212A2 (en) * 2007-03-26 2010-01-13 International Aids Vaccine Initiative Method of elicting immune response with a modified mva viral hiv-1 vector
KR101238795B1 (ko) 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
AU2008339984A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
NZ596171A (en) 2008-07-16 2012-05-25 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef to dendritic cells
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2344143A1 (en) 2008-09-09 2011-07-20 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
MX2012001075A (es) 2009-07-24 2012-05-22 Immune Design Corp Vectores lentivirales pseudotipificados con una glicoproteina de envoltura de virus sindbis.
WO2011117408A1 (en) * 2010-03-26 2011-09-29 Glaxosmithkline Biologicals S.A. Hiv vaccine
JP6030052B2 (ja) * 2010-05-14 2016-11-24 バクスアルタ インコーポレイテッド Ｏｓｐａキメラおよびそのワクチンでの使用法
EP2621528A1 (en) * 2010-09-27 2013-08-07 GlaxoSmithKline Biologicals S.A. Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
MX362699B (es) 2012-03-30 2019-02-01 Immune Design Corp Partículas de vectores lentivirales teniendo eficiencia de transducción mejorada para células que expresan dc-sign.
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
BR112022009421A2 (pt) 2019-11-14 2022-10-25 Aelix Therapeutics S L Regimes de dosagem para vacinas
CN115666634A (zh) 2020-03-27 2023-01-31 瑞典疫苗制药有限公司 用于治疗和预防冠状病毒的组合物和方法
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
TW202330575A (zh) 2021-09-29 2023-08-01 瑞典商斯文斯卡疫苗生產股份有限公司 用於治療及預防冠狀病毒之組成物及方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
DK0761231T3 (da) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5962635A (en) * 1993-05-18 1999-10-05 Biomolecular Research Institute Ltd. Therapeutic compounds
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
JP5220248B2 (ja) 1997-08-29 2013-06-26 アンチジェニックス・インコーポレイテッド アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU762376C (en) 1998-08-04 2004-10-14 Henry M. Jackson Foundation, The Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
AU782193B2 (en) 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
AU2001294562B2 (en) 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1427826B1 (en) * 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
IL161584A0 (en) 2001-11-21 2004-09-27 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
ES2285174T3 (es) * 2002-06-11 2007-11-16 Glaxosmithkline Biologicals S.A. Composiciones inmunogenicas.
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
CA2539864A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines

Also Published As

Publication number Publication date
CN101035897A (zh) 2007-09-12
HK1108168A1 (en) 2008-05-02
JP2011234722A (ja) 2011-11-24
AU2005268856A1 (en) 2006-02-09
EP2130921A3 (en) 2010-03-03
PT1773999E (pt) 2009-12-16
CA2575898C (en) 2015-09-29
MX2007001515A (es) 2007-09-07
SI1773999T1 (sl) 2010-01-29
MY145614A (en) 2012-03-15
US20100184836A1 (en) 2010-07-22
RU2441878C2 (ru) 2012-02-10
BRPI0514108A (pt) 2008-05-27
NO20070988L (no) 2007-05-04
IL180947A0 (en) 2007-07-04
WO2006013106A3 (en) 2006-08-17
GB0417494D0 (en) 2004-09-08
DE602005016810D1 (de) 2009-11-05
EP2130921A2 (en) 2009-12-09
KR101501495B1 (ko) 2015-03-11
CA2575898A1 (en) 2006-02-09
JP5629647B2 (ja) 2014-11-26
KR20070041765A (ko) 2007-04-19
AR050102A1 (es) 2006-09-27
TW200621806A (en) 2006-07-01
US7612173B2 (en) 2009-11-03
US20070243203A1 (en) 2007-10-18
RU2007104088A (ru) 2008-09-10
EP2280073A2 (en) 2011-02-02
EP1773999A2 (en) 2007-04-18
ES2486669T3 (es) 2014-08-19
CY1109667T1 (el) 2014-08-13
MA28983B1 (fr) 2007-11-01
HRP20090678T1 (hr) 2010-01-31
IL207575A0 (en) 2011-07-31
ES2445453T3 (es) 2014-03-03
EP2280073B1 (en) 2014-06-11
NZ552976A (en) 2010-01-29
JP2014239687A (ja) 2014-12-25
EP1773999B1 (en) 2009-09-23
JP2008507987A (ja) 2008-03-21
DK1773999T3 (da) 2010-01-18
ATE443769T1 (de) 2009-10-15
CN101035897B (zh) 2012-02-01
EP2280073A3 (en) 2011-06-29
ZA200700771B (en) 2009-04-29
WO2006013106A2 (en) 2006-02-09
ES2334044T3 (es) 2010-03-04
AR080216A2 (es) 2012-03-21
JP6007212B2 (ja) 2016-10-12
CN102633866B (zh) 2015-04-15
SG155206A1 (en) 2009-09-30
PL1773999T3 (pl) 2010-02-26
CN102633866A (zh) 2012-08-15
EP2130921B1 (en) 2013-11-20
PE20060577A1 (es) 2006-08-07
AU2005268856B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
TWI365191B (en) Vaccine
IL178890A0 (en) Vaccines
GB0922611D0 (en) Improved vaccines
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
GB0409940D0 (en) Vaccine
GB0420634D0 (en) Vaccines
GB0411150D0 (en) Vaccine
ZA200709207B (en) Vaccine
GB0413510D0 (en) Vaccine
GB0515135D0 (en) Vaccine
GB0810662D0 (en) Vaccine
GB0516944D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB0428381D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
IL179254A0 (en) An anti-theileriosis vaccine
GB0412547D0 (en) Vaccine
GB0413371D0 (en) Vaccine
GB0413513D0 (en) Vaccine
GB0416398D0 (en) Vaccine
GB0416833D0 (en) Vaccine
GB0413154D0 (en) Vaccine
GB0425339D0 (en) Vaccine

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees